Roth MKM analyst Kumaraguru Raja downgraded Apexigen to Neutral from Buy with a $1.40 price target following the company’s announcement that is was evaluating strategic alternatives and restructuring, citing uncertainty in strategy and a lack of clarity on the future of the company following the news. However, the firm still believes that liposarcoma "offers an achievable path to market" for sotigalimab given the significant unmet need and "promising" Phase 2 data.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APGN: